Prevention & care

Multiple myeloma: plasma cells, MGUS, smoldering disease, protein tests, defining events, and care

10 sources · Latest source check 2026-10-08 UTC

On this page

Myeloma is a blood cancer involving abnormal plasma cells in bone marrow. It can affect bones, kidneys and immune function; bone pain is not the whole disease. Myeloma cannot usually be cured, but treatment can manage it.[1]

A monoclonal protein does not identify one uniform disease

A monoclonal protein does not identify one uniform disease
Setting	Broad distinction
MGUS	A precursor finding without the defining myeloma damage/events.[3]
Smoldering myeloma	Meets specified clonal/protein criteria without myeloma-defining events.[3]
Active myeloma	Clonal findings plus attributable damage or defining biomarkers.[3]
Solitary plasmacytoma	A localized plasma-cell tumor with a separate assessment.[2]

M protein is not the same as useful immune protection

NCI explains that normal plasma cells produce antibodies, while abnormal cells can produce a monoclonal protein that does not provide normal infection protection. The protein can contribute to other problems. A high antibody-related measurement therefore cannot be treated as proof of strong immunity or confused with dietary protein intake.[2]

MGUS is not automatically active cancer

IMWG distinguishes MGUS from active myeloma using clonal cells, protein findings and attributable damage. Progression is not inevitable. Monitoring needs the actual classification; a protein’s presence alone does not select treatment.[3]

CRAB describes four damage domains, not a stand-alone diagnosis

CRAB refers to calcium elevation, renal problems, anemia and destructive bone lesions attributable to the plasma-cell disorder. IMWG also includes specified myeloma-defining biomarkers. Thus, absence of symptoms does not automatically establish smoldering disease, and kidney disease or anemia alone does not establish myeloma. The whole assessment matters.[3]

A bone-density test cannot by itself classify myeloma bone disease

IMWG distinguishes destructive bone lesions from osteoporosis and explains that bone densitometry alone is insufficient for myeloma diagnosis. Ask which imaging finding is present and what it means in context. Low bone density, a compression fracture and a documented myeloma lesion are not interchangeable labels.[3]

Back or rib pain, fatigue and thirst have several possible causes

NHS lists those symptoms alongside weakness, breathlessness and unexplained weight loss; some myeloma is found during testing for another reason. Symptoms overlap other conditions. They need assessment rather than a self-diagnosis, and an incidental test finding still needs its full classification.[4]

Sudden loss of function can require emergency assessment

NHS advises emergency help for sudden inability to walk or stand, loss of limb feeling, confusion or loss of bowel/bladder control. Serious complications need immediate evaluation. Use local emergency services and the cancer team’s instructions rather than waiting for a routine visit or assuming new weakness is ordinary fatigue.[4]

Blood, marrow and imaging findings supply different information

NHS describes marrow sampling and CT or MRI, with further tests as needed. A suspicious scan, monoclonal protein and clonal marrow cells are different findings. Ask what each establishes, which alternative explanations remain and whether further specialist assessment is needed.[5]

Myeloma staging is not simply a map of one tumor’s spread

NCI describes blood proteins in myeloma staging and additional chromosome or LDH findings in selected risk assessment. Ask which staging or risk system the team uses and what it predicts. A stage number is not a personal survival deadline, and this overview does not reproduce complete current staging criteria.[2]

Control of disease and protection of organs both matter

NHS describes combinations of cancer-directed medicines, selected radiation and bone-protection treatment. The plan depends on symptoms, prior care and health. Ask separately about cancer response, pain, kidney function, bone safety, infection and adverse effects; a fall in one blood marker cannot settle every goal.[6]

Blood-forming-cell transplant supports recovery after intensive treatment

NCI explains that high-dose chemotherapy also damages healthy blood formation. Stored blood-forming stem cells are infused to restore it. This is a specific cancer-care procedure, not an ordinary anti-aging treatment or a guarantee of permanent cure; suitability and risks need specialist discussion.[2]

AQUILA studied selected high-risk smoldering disease

The Janssen-funded report randomized 390 participants to daratumumab or active monitoring. Its primary endpoint was progression to active myeloma or death, with median follow-up of 65.2 months. Trial eligibility and high-risk labels need their specific definitions; it did not establish benefit for MGUS or every lower-risk smoldering setting.[7]

Benefit and adverse events should be read together

Five-year progression-free survival was 63.1% versus 40.8%; overall survival was 93.0% versus 86.9%, with 15 versus 26 deaths. Grade 3–4 hypertension occurred in 5.7% versus 4.6%. These are different endpoints in a selected trial. Limited deaths, follow-up and subsequent care matter when interpreting survival; no personal treatment is chosen here.[7]

The published correction changes a table footnote

The April 2026 NEJM notice corrects an M-protein threshold in a table footnote by a factor of ten and states that the online article is corrected. A copied numerical eligibility rule must use the corrected source. This overview supplies no self-applied threshold or dosing schedule.[8]

Published correspondence questioned the survival interpretation

A 2025 letter raised questions about treatment received after progression in the monitoring group. Only its indexed excerpt was inspected; the full exchange and subsequent treatment data need independent appraisal. The criticism is recorded as interpretation of the same trial, not a separate randomized replication or a resolved verdict on individual care.[9]

The FDA indication is restricted to high-risk smoldering disease

FDA’s November 2025 notice explicitly excludes other smoldering-risk categories from this indication. It also lists important precautions, including administration reactions, infection, reduced blood counts, pregnancy-related harm and interference with blood-bank testing. Ask about absolute benefit, harms, risk classification, local approval and access. A US approval is not automatically a worldwide care policy.[10]

Relapse, symptoms and support need a continuing plan

NHS describes care for disease that returns and a specialist nurse as a contact during and after treatment. Ask which tests track response, which new symptoms need urgent help, and where to obtain practical and emotional support. Earlier response and later disease control are separate questions.[6][5]

Evidence & uncertainty

Early treatment of selected high-risk smoldering disease changed with a November 2025 US approval. That does not apply to every smoldering-risk group. The associated trial also has a 2026 table correction and published criticism of survival interpretation. Approval, individual benefit and unresolved appraisal questions should remain distinct.[10][8][9]

Selected-source overview · Independent review pending

Published questions

Does MGUS automatically mean active multiple myeloma?

Selected-source overview · Independent review pending. Read the evidence context.

Its defining context differs from active disease.[3]

Evidence behind this answer

IMWG Criteria for the Diagnosis of Multiple Myeloma
agency condition or prevention explanation · Date not stated
Selected relevant original official page passages inspected · Precursor distinctions, attributable CRAB damage, defining biomarkers and bone-imaging limits